Peter T Nash

46PUBLICATIONS
160CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Toxicology (incl. clinical toxicology)Rheumatology and arthritisPhysiotherapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Jun 02, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

|Mar 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.

Philip J Mease, Joseph F Merola, Marina Magrey

|Dec 01, 2025
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab.

William Tillett, Laura C Coates, Marijn Vis

|Apr 17, 2025
Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis.

Dafna D Gladman, Maxime Dougados, Helena Marzo-Ortega

|Nov 26, 2024
A review and recommendations on the management of psoriatic arthritis in Australia 2024.

Peter Nash, Daniel Sumpton, Michelle Tellus

|Oct 04, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study.

Philip J Mease, Xenofon Baraliakos, Vinod Chandran

Pageof 8

Frequent Collaborators

10 joint publications

Philip Mease

7 joint publications

Kevin L Winthrop

6 joint publications

Yoshiya Tanaka

6 joint publications

Désirée van der Heijde